Skip to main content

Table 2 Prognostic factors for OS (N = 74)

From: Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Variables Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
ECOG     
 0–1 versus > 1 0.33 (0.15, 0.71) 0.005 0.34 (0.15, 0.78) 0.011
Oligometastasis     
 Yes versus no 0.22 (0.07, 0.74) 0.015 0.28 (0.08, 0.97) 0.044
Treatment     
 anti-PD-1/TA + SBRT vs anti-PD-1/TA alone 0.42 (0.20, 0.90) 0.026 0.43 (0.19, 0.98) 0.044
Duration of first-line therapy     
  ≥8.6 m versus 8.6 m 0.46 (0.22, 0.99) 0.046 0.42 (0.19, 0.91) 0.027